Forvis Mazars Wealth Advisors’s DexCom DXCM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $995K | Sell |
15,838
-39
| -0.2% | -$2.72K | 0.02% | 210 |
|
|
2025
Q4 | $1.05M | Buy |
15,877
+814
| +5% | +$52.6K | 0.02% | 202 |
|
|
2025
Q3 | $1.01M | Sell |
15,063
-650
| -4% | -$51.4K | 0.02% | 208 |
|
|
2025
Q2 | $1.37M | Sell |
15,713
-1,768
| -10% | -$139K | 0.03% | 183 |
|
|
2025
Q1 | $1.19M | Hold |
17,481
| – | – | 0.03% | 193 |
|
|
2024
Q4 | $1.36M | Buy |
17,481
+118
| +0.7% | +$8.74K | 0.03% | 190 |
|
|
2024
Q3 | $1.16M | Buy |
17,363
+680
| +4% | +$55.8K | 0.03% | 215 |
|
|
2024
Q2 | $1.89M | Sell |
16,683
-5
| -0% | -$632 | 0.05% | 167 |
|
|
2024
Q1 | $2.31M | Buy |
16,688
+307
| +2% | +$38.6K | 0.06% | 149 |
|
|
2023
Q4 | $2.03M | Buy |
16,381
+110
| +0.7% | +$11.2K | 0.06% | 154 |
|
|
2023
Q3 | $1.52M | Sell |
16,271
-17
| -0.1% | -$1.92K | 0.05% | 173 |
|
|
2023
Q2 | $2.09M | Hold |
16,288
| – | – | 0.06% | 157 |
|
|
2023
Q1 | $1.89M | Buy |
16,288
+2
| +0% | +$224 | 0.06% | 155 |
|
|
2022
Q4 | $1.84M | Buy |
16,286
+25
| +0.2% | +$2.75K | 0.06% | 152 |
|
|
2022
Q3 | $1.31M | Sell |
16,261
-67
| -0.4% | -$5.67K | 0.05% | 176 |
|
|
2022
Q2 | $1.22M | Buy |
16,328
+48
| +0.3% | +$4.38K | 0.05% | 172 |
|
|
2022
Q1 | $2.08M | Hold |
16,280
| – | – | 0.09% | 106 |
|
|
2021
Q4 | $2.19M | Sell |
16,280
-4
| -0% | -$575 | 0.09% | 96 |
|
|
2021
Q3 | $2.23M | Buy |
16,284
+8
| +0% | +$1.01K | 0.1% | 91 |
|
|
2021
Q2 | $1.74M | Sell |
16,276
-8
| -0% | -$768 | 0.08% | 104 |
|
|
2021
Q1 | $1.46M | Sell |
16,284
-652
| -4% | -$61.2K | 0.07% | 111 |
|
|
2020
Q4 | $1.56M | Sell |
16,936
-192
| -1% | -$17.1K | 0.08% | 118 |
|
|
2020
Q3 | $1.76M | Buy |
17,128
+128
| +0.8% | +$13.4K | 0.1% | 97 |
|
|
2020
Q2 | $1.72M | Buy |
17,000
+188
| +1% | +$16.8K | 0.11% | 94 |
|
|
2020
Q1 | $1.13M | Sell |
16,812
-12
| -0.1% | -$747 | 0.09% | 102 |
|
|
2019
Q4 | $920K | Buy |
16,824
+228
| +1% | +$10.8K | 0.07% | 122 |
|
|
2019
Q3 | $619K | Hold |
16,596
| – | – | 0.05% | 142 |
|
|
2019
Q2 | $622K | Buy |
16,596
+16
| +0.1% | +$503 | 0.05% | 142 |
|
|
2019
Q1 | $494K | Hold |
16,580
| – | – | 0.04% | 164 |
|
|
2018
Q4 | $497K | Sell |
16,580
-76
| -0.5% | -$2.41K | 0.05% | 137 |
|
|
2018
Q3 | $596K | Hold |
16,656
| – | – | 0.05% | 132 |
|
|
2018
Q2 | $395K | Sell |
16,656
-260
| -2% | -$5.51K | 0.04% | 171 |
|
|
2018
Q1 | $314K | Buy |
16,916
+300
| +2% | +$4.44K | 0.03% | 190 |
|
|
2017
Q4 | $238K | Buy |
16,616
+220
| +1% | +$2.86K | 0.02% | 224 |
|
|
2017
Q3 | $201K | Buy |
+16,396
| New | +$290K | 0.02% | 219 |
|
|
2014
Q2 | – | Sell |
-20,000
| Closed | -$207K | – | 145 |
|
|
2014
Q1 | $207K | Buy |
+20,000
| New | +$207K | 0.04% | 152 |
|
Other funds holding DXCM
VCM
VPM
Forvis Mazars Wealth Advisors's DXCM Position: Q1 2026 in Review
Forvis Mazars Wealth Advisors reduced its DexCom (DXCM) stake by 0.25% in Q1 2026, selling an estimated $2.72K and leaving 15,838 shares worth $995K. The position accounts for 0.02% of the portfolio, ranked #210.
Forvis Mazars Wealth Advisors first reported a position in DXCM in Q1 2014 and has held it in 36 quarters since. The position peaked at $2.31M in Q1 2024. 956 funds tracked by Wall St. Rank hold DXCM as of Q1 2026.
- Forvis Mazars Wealth Advisors held 15,838 shares of DexCom worth $995K as of Q1 2026.
- Forvis Mazars Wealth Advisors sold 39 DexCom shares in Q1 2026, an estimated $2.72K.
- DexCom made up 0.02% of Forvis Mazars Wealth Advisors's portfolio in Q1 2026, its #210 holding.
- Forvis Mazars Wealth Advisors first reported a position in DexCom in Q1 2014 and has held it in 36 quarters since.
- Forvis Mazars Wealth Advisors's DexCom position peaked at $2.31M in Q1 2024.
- 956 funds tracked by Wall St. Rank held DexCom as of Q1 2026.
Based on Forvis Mazars Wealth Advisors's 13F filing for Q1 2026, filed 1 May 2026.